-transparent.png){kind=logo}
A Phase I study of pentamethylmelamine (PMM) was conducted, administering the drug as a 24-hr i.v. infusion once weekly for 3 weeks. Doses ranged from 80 to 3000 mg/sq m/week. Twenty-six evaluable patients received a total of 30 courses of PMM. The median performance status of the patients was 60% (range, 40 to 90%), and the median age was 58 years (range, 43 to 72 years). The highest tolerated dose was 2000 mb/sq m/week. Nausea and vomiting were the dose-limiting toxicities; myelosuppression was neither consistent nor severe. One objective response lasting 10 months was noted in a patient with renal cancer. Pharmacokinetic studies using [ring-14C]PMM demonstrated a postinfusion half-life of 14C of approximately 12 hr, with the majority of the radiolabel excreted in the urine. PMM was introduced as a parenteral form of hexamethylmelamine. The present schedule does not permit administration of PMM in a dose greater than the tolerated dose of hexamethylmelamine and does not appear to offer an advantage over the p.o. use of the parent compound.
E S Casper, and
R J Gralla, and
G R Lynch, and
B R Jones, and
T M Woodcock, and
C Gordon, and
D P Kelsen, and
C W Young
March 1994,
Journal of the National Cancer Institute,
E S Casper, and
R J Gralla, and
G R Lynch, and
B R Jones, and
T M Woodcock, and
C Gordon, and
D P Kelsen, and
C W Young
September 1982,
Cancer research,
E S Casper, and
R J Gralla, and
G R Lynch, and
B R Jones, and
T M Woodcock, and
C Gordon, and
D P Kelsen, and
C W Young
October 1994,
Japanese journal of cancer research : Gann,
E S Casper, and
R J Gralla, and
G R Lynch, and
B R Jones, and
T M Woodcock, and
C Gordon, and
D P Kelsen, and
C W Young
January 1998,
Annals of oncology : official journal of the European Society for Medical Oncology,
E S Casper, and
R J Gralla, and
G R Lynch, and
B R Jones, and
T M Woodcock, and
C Gordon, and
D P Kelsen, and
C W Young
July 1995,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E S Casper, and
R J Gralla, and
G R Lynch, and
B R Jones, and
T M Woodcock, and
C Gordon, and
D P Kelsen, and
C W Young
September 1988,
Journal of the National Cancer Institute,
E S Casper, and
R J Gralla, and
G R Lynch, and
B R Jones, and
T M Woodcock, and
C Gordon, and
D P Kelsen, and
C W Young
May 1983,
Cancer treatment reports,
E S Casper, and
R J Gralla, and
G R Lynch, and
B R Jones, and
T M Woodcock, and
C Gordon, and
D P Kelsen, and
C W Young
February 1993,
Cancer research,
E S Casper, and
R J Gralla, and
G R Lynch, and
B R Jones, and
T M Woodcock, and
C Gordon, and
D P Kelsen, and
C W Young
May 1989,
European journal of cancer & clinical oncology,
E S Casper, and
R J Gralla, and
G R Lynch, and
B R Jones, and
T M Woodcock, and
C Gordon, and
D P Kelsen, and
C W Young
May 1993,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
